Document:

<Page>
                                                                  EXHIBIT 10.16

              FIFTH AMENDED AND RESTATED STOCKHOLDERS' AGREEMENT

      THIS FIFTH AMENDED AND RESTATED STOCKHOLDERS' AGREEMENT (the
"AGREEMENT"), is made and entered into as of January 19, 2006, by and among
Metabolix, Inc., a corporation organized under the laws of the State of
Delaware (the "COMPANY"), the holders of the Company's common stock, $.01 par
value ("COMMON STOCK") or preferred stock, $.01 par value ("PREFERRED STOCK")
listed on Exhibit A (the "EXISTING STOCKHOLDERS") and any additional
stockholder of the Company (collectively, the "ADDITIONAL STOCKHOLDERS", and
with the Existing Stockholders, the "STOCKHOLDERS") who becomes a party
hereto by signing an Additional Stockholder Signature Page (an "ADDITIONAL
STOCKHOLDER SIGNATURE PAGE") in the form attached hereto as EXHIBIT B.

      WHEREAS, the Company and the Existing Stockholders are parties to that
certain Fourth Amended and Restated Stockholders' Agreement dated as of April
2, 2004 (the "FOURTH AMENDED STOCKHOLDERS' AGREEMENT");

      WHEREAS, certain purchasers (the "PURCHASERS") are acquiring shares of
Series 05 Convertible Preferred Stock, $.01 par value per share, (the "SERIES
05 PREFERRED STOCK") pursuant to that certain Series 05 Preferred Stock
Purchase Agreement (the "PURCHASE AGREEMENT") by and between the Company and
the Purchasers;

      WHEREAS, pursuant to Section 6.4 of the Fourth Amended Stockholders'
Agreement, the Fourth Amended Stockholders' Agreement may be amended upon the
written consent of the Company and each of Edward M. Giles, State Farm Mutual
Automobile Insurance Company, Vertical Fund I, L.P. and Vertical Fund II,
L.P.; and

      WHEREAS, as an inducement to the Purchasers to purchase the Series 05
Preferred Stock pursuant to the Purchase Agreement the parties hereto desire
to amend the Fourth Amended Stockholders' Agreement on the terms and
conditions set forth herein.

      NOW THEREFORE, in consideration of the premises and of the mutual
promises hereinafter set forth, the parties hereby agree to amend and restate
the Fourth Stockholders' Agreement in its entirety as follows:

                                   ARTICLE I

                           COVENANTS OF THE COMPANY

      1.1   CORPORATE EXISTENCE. The Company shall maintain its corporate
existence and qualification and make no material change (directly or through
subsidiaries) in the present nature of the Company's business without the
consent of a majority of the Stockholders.

      1.2   RULE 144 COMPLIANCE. With a view to making available the benefits
of certain rules and regulations of the Securities and Exchange Commission
(the "COMMISSION") which may permit the sale of the shares to the public
without registration, at all times after ninety (90) days after a
registration statement covering an initial public offering of securities of
the Company

<Page>

under the Securities Act of 1933, as amended (the "1933 ACT") shall have
become effective, the Company agrees to:  (i) make and keep public
information available, as those terms are understood and defined in Rule 144
under the 1933 Act; (ii) use commercially reasonable efforts to file with the
Commission in a timely manner all reports and other documents required of the
Company under the 1933 Act and the Securities Exchange Act of 1934, as
amended (the "EXCHANGE ACT"); (iii) furnish to each holder of Registrable
Securities (as hereinafter defined) forthwith upon request a written
statement by the Company as to the Company's compliance with the reporting
requirements of Rule 144 and of the 1933 Act and the Exchange Act, a copy of
the most recent annual or quarterly report of the Company, and such other
reports and documents so filed by the Company as such holder may reasonably
request in availing itself of any rules or regulation of the Commission
allowing such holder to sell any Registrable Securities (as hereinafter
defined) without registration; and (iv) use commercially reasonable efforts
to satisfy the requirements of all such rules and regulations (including the
requirements for current public information, registration under the Exchange
Act and timely reporting to the Commission) at the earliest possible date
after its first registered public offering.

      1.3   FINANCIAL INFORMATION.

            (a)   As soon as practicable after the end of each fiscal year,
      and in any event within 120 days thereafter, the Company agrees to
      provide the Stockholders with copies of consolidated balance sheets of
      the Company as of the end of such fiscal year, and consolidated
      statements of income and consolidated statements of changes in cash
      flow of the Company for such fiscal year, prepared in accordance with
      generally accepted accounting principles, all in reasonable detail and
      reviewed by independent public accountants selected by the Company.

            (b)   As soon as practicable after the end of the first, second
      and third quarterly accounting periods in each fiscal year of the
      Company,  the Company agrees to provide the Stockholders with copies of
      a consolidated balance sheet of the Company as of the end of each such
      quarterly period, and consolidated statements of income and
      consolidated statements of change in cash flow of the Company for such
      period and for the current fiscal year to date, if and to the extent
      that such statements are prepared by the Company.

                                  ARTICLE II

                              REGISTRATION RIGHTS

      2.1   PIGGYBACK REGISTRATION RIGHTS. Whenever the Company proposes to
register any stock or other securities for the Company's own or others'
account under the 1933 Act for a public offering for cash, other than in its
initial public offering or in a registration on Form S-4 or S-8 under the
1933 Act or any successor forms thereto, the Company shall give each holder
of Registrable Securities written notice prior to such registration. Upon the
written request of any such holder given within twenty (20) days after
receipt of such notice, the Company will use its best efforts to cause to be
included in such registration all of the Registrable Securities that such
holder requests to be registered.

                                       2

<Page>

      2.2   DEMAND REGISTRATION RIGHTS. At any time after the Company becomes
subject to the periodic reporting requirements of Section 13 or Section 15(d)
of the Exchange Act, one or more of the holders of at least 30% of the
Registrable Securities may make a written request for registration (a "DEMAND
REGISTRATION") under the 1933 Act with respect to all or part of the
Registrable Securities owned by the Stockholder. Any such request must
specify the number and type of Registrable Securities proposed to be sold by
the Stockholder and the intended method of disposition. Upon receipt of such
written request, the Company will notify all holders of all Registrable
Securities of the request. Upon written request of any holder given within 20
days after receipt by such holder from the Company of such notification, the
Company will use its best efforts to cause such of the Registrable Securities
as may be requested by any holder thereof (including the holder or holders
giving the initial notice of intent to offer) to be registered under the
Securities Act as expeditiously as possible; provided, however, that the
minimum market value of any offering and registration of Registrable
Securities made pursuant to this Section 2.2 shall be at least $2,000,000.
However, the Company will be entitled to postpone, for a reasonable period of
time but in no event more than 180 days after the date of its receipt of such
a request pursuant to this Section 2.2, the filing of any registration
statement or offering and sale, if the Company determines, in its reasonable
business judgment, that the proposed registration or the offering would be
materially detrimental to the Company and gives the Stockholders written
notice of such determination. If the Company postpones the filing of any
registration statement or offering and sale, the Stockholders will have the
right to withdraw the request for registration by giving notice to the
Company within 15 days after receipt from the Company of the notice of
postponement. If the Stockholders withdraw their request for registration,
such request will not be counted for purposes of determining the number of
Demand Registrations to which the Stockholders are entitled under this
Section 2.2.

      The Stockholders may instruct the Company to withdraw any registration
statement filed under this Section 2.2, and the Company will withdraw such
registration statement, if prior to the effective date thereof the
Stockholders learn of a material adverse change in the business, condition or
prospects of the Company unknown to the Stockholders at the time the
registration was requested. In addition, the Stockholders may, before or
after a registration statement becomes effective, withdraw their Registrable
Securities from the offering by giving notice of such withdrawal to the
Company, in which event such registration will be deemed to have occurred for
the purposes of this Section 2.2 unless the Stockholders, within 20 days
after such withdrawal, agree in writing to pay all the out-of-pocket expenses
of the Company incurred in connection with such withdrawn registration and
pay all such expenses in full within 10 days after receipt of a statement
therefor setting forth the amounts of such expenses in reasonable detail.

      Except in the case of a withdrawal provided for in the preceding
paragraph or a registration from which 20% or more of the Registrable
Securities requested to be registered are excluded by the book-running
managing underwriter pursuant to Section 2.3, the Company will not be
required to effect more than two Demand Registrations pursuant to this
Agreement.

      If within 20 days after a request for Demand Registration has been made
pursuant to this Section 2.2 the Company notifies the Stockholders that the
Company wishes either to include an offering of its own securities for its
own account or to register securities for its own account on

                                       3

<Page>

the registration statement being filed pursuant to the Stockholders' demand,
such additional securities will be included and the registration will not be
counted in determining the number of Demand Registrations to which the
Stockholders are entitled. Unless otherwise agreed in writing by the
Stockholders, no security holder of the Company other than the Stockholders
will be permitted to offer securities of the Company pursuant to any Demand
Registration pursuant to this Section 2.2.

      The Stockholders will select the book-running managing underwriter and
any other investment bankers and underwriters to be used in connection with
an offering pursuant to this Section 2.2, subject to the Company's approval,
which approval will not unreasonably be withheld or delayed.

      2.3   REDUCTION OF OFFERING. Notwithstanding anything else in this
Agreement, if in the opinion of the book-running managing underwriter of an
offering described in Section 2.1 or Section 2.2 (i) the size of the
offering, or (ii) the combination of securities proposed to be included in
such offering are such that the success of the offering would be materially
and adversely affected by the inclusion of Registrable Securities, then:

            (a)   if the size of the offering is the basis for such
      underwriter's opinion, the amount of Registrable Securities to be
      offered for the account of the Stockholders will be reduced to the
      extent necessary to reduce the total amount of securities to be
      included in such offering to the amount recommended by such
      underwriter; provided, that (x) in the case of a Demand Registration,
      the amount of Registrable Securities to be offered by, on behalf of, or
      for the account of the Stockholders will be reduced only after the
      amount of securities to be offered for the account of the Company and
      any security holders, other than the Stockholders, has been reduced to
      zero and (y) in the case of a Piggyback Registration, where securities
      are being offered by or for the account of anyone other than the
      Company, then the proportion by which the aggregate amount of such
      Registrable Securities intended to be offered by or for the account of
      the Stockholders is reduced will not exceed the proportion by which the
      amount of such securities intended to be offered for the account of
      such other selling shareholder is reduced; and

            (b)   if the combination of securities to be offered is the basis
      for such underwriter's opinion, the Registrable Securities to be
      included in such offering will be reduced as described in paragraph (a)
      above, except that in the case of a Piggyback Registration, if the
      reduction described in clause (y) of paragraph (a) would, in the
      judgment of the book-running managing underwriter, be insufficient
      substantially to eliminate the adverse effect that inclusion of the
      Registrable Securities requested to be included would have on such
      offering, such Registrable Securities will be excluded from such
      offering.

      2.4   DEFINITION OF REGISTRABLE SECURITIES. "REGISTRABLE SECURITIES"
means (i) the shares of Common Stock currently issued to the Stockholders and
those issuable upon conversion of the Preferred Stock and exercise of
warrants to purchase Common Stock; (ii) any shares of Common Stock of the
Company acquired by any Stockholder after the date hereof pursuant to a right
of first refusal or pursuant to pre-emptive rights and (iii) any shares of

                                       4

<Page>

Common Stock acquired by any Stockholder after the date hereof pursuant to a
dividend or other distribution with respect to, or in exchange for or in
replacement of, such Common Stock, Preferred Stock or Common Stock issued on
conversion or exercise thereof; provided, however, that shares of Common
Stock which are Registrable Securities shall cease to be Registrable
Securities upon any sale pursuant to a registration statement under the 1933
Act, Section 4(1) of the 1933 Act or Rule 144 promulgated under the 1933 Act.
Registrable Securities shall not include Common Stock, Preferred Stock, or
any shares of Common Stock issued or issuable upon conversion thereof, which
are available for sale and can be sold (whether or not so sold) pursuant to
Rule 144A or Rule 144 of the 1933 Act, or any similar rule promulgated by the
Commission permitting the resale of restricted securities without the
necessity of a registration statement under the 1933 Act.

      2.5   REGISTRATION PROCEDURES. All expenses incurred in connection with
the registrations under this Article II (including all registration, filing,
listing, qualification, printer's and accounting fees and up to $5,000 for
legal fees of one counsel for all Stockholders but excluding underwriting
commissions and discounts) shall be borne by the Company. If and whenever the
Company is under an obligation pursuant to this Article II to effect or use
the Company's best efforts to effect a registration of any Registrable
Securities, the Company shall: (a) use the Company's best efforts to prepare
and file with the Commission as soon as reasonably practicable, a
registration statement with respect to the Registrable Securities and use the
Company's best efforts to cause such registration to promptly become and
remain effective for a period of at least one hundred twenty (120) days (or
such shorter period during which the distribution described in the
Registration Statement has been completed); (b) use the Company's best
efforts to register and qualify the Registrable Securities covered by such
registration statement under applicable state securities laws; (c) provide a
transfer agent for the Common Stock no later than the effective date of the
first registration of any Registrable Securities, (d) list such Registrable
Securities on any national securities exchange or the NASDAQ National Market
System, or if the Common Stock is unable to be so listed, use the Company's
best efforts to qualify the Registrable Securities for inclusion on any other
automated quotation system of the National Association of Securities Dealers,
Inc.; and (e) take such other actions as are reasonable or necessary to
comply with the requirements of the 1933 Act and the regulations thereunder,
or the reasonable request of any holder, with respect to the registration and
distribution of the Registrable Securities. The Company is not obligated to
effect registration or qualification under this Article II in any
jurisdiction requiring the Company to qualify to do business (unless the
Company is otherwise required to be so qualified) or to execute a general
consent to service of process.

      2.6   UNDERWRITING ARRANGEMENT. Registration pursuant to Article II
covering an underwritten public offering, shall be conditioned upon each
participating holder entering into a written agreement with the managing
underwriter in such form and containing such provisions as are reasonably
acceptable to each such participating holder and are customary in the
securities business for such an arrangement between such underwriter and
companies of the Company's size and investment stature.

      2.7   NOTIFICATION. The Company shall promptly notify each holder of
Registrable Securities covered by any registration statement of any event, of
which the Company has

                                       5

<Page>

knowledge, that results in the prospectus included in such registration
statement, as then in effect, containing an untrue statement of a material
fact or omitting to state a material fact required to be stated therein or
necessary to make the statement therein not misleading in light of the
circumstances then existing.

      2.8   FURNISHING OF DOCUMENTS. At the request of any participating
holder, the Company will furnish to each underwriter, if any, and
participating holders, a legal opinion of its counsel and a "cold comfort"
letter from its independent certified public accountants, each in customary
form and substance, at such time or times as such documents are customarily
provided in the type of offering involved. As expeditiously as possible, the
Company shall furnish to each participating holder such reasonable numbers of
copies of the prospectus, including a preliminary prospectus, in conformity
with the requirements of the 1933 Act, and such other documents as the
participating holder may reasonably request in order to facilitate the public
sale or other disposition of the Registrable Securities owned by the
participating holders.

      2.9   INDEMNIFICATION AND CONTRIBUTION.

      (a)   In the event of a registration of any of the Registrable
Securities under the 1933 Act pursuant to Article II, the Company will
indemnify and hold harmless the Stockholders, and each other person, if any,
who controls the Stockholders within the meaning of the 1933 Act, and each
employee, officer and trustee of the Stockholders, against any losses,
claims, damages or liabilities, joint or several, to which the Stockholders,
or each such controlling person, employee, officer or trustee may become
subject under the 1933 Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are
based upon any untrue statement or alleged untrue statement of any material
fact contained in any registration statement under which such Registrable
Securities were registered under the 1933 Act pursuant to Article II, any
preliminary prospectus or final prospectus contained therein or any amendment
or supplement thereof or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, and will
reimburse the Stockholders, and each such controlling person, employee,
officer or trustee for any legal or other expenses reasonably incurred by
them in connection with investigating or defending any such loss, claim,
damage, liability or action; provided that the Company will not be liable in
any such case if and to the extent that any such loss, claim, damage or
liability arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission so made in conformity with
information furnished by the Stockholders or any such controlling person,
employee, officer or trustee in writing specifically for use in such
registration statement or prospectus.

      (b)   In the event of a registration of any of the Registrable
Securities under the 1933 Act pursuant to Article II, each holder of
Registrable Securities included in such registration will indemnify and hold
harmless the Company, each person, if any, who controls the Company within
the meaning of the 1933 Act, each officer of the Company who signs the
registration statement, each director of the Company, and each underwriter
and person who controls any underwriter within the meaning of the 1933 Act,
against all losses, claims, damages or liabilities, joint or several, to
which the Company or such officer, director, underwriter or controlling
person may become subject under the 1933 Act or otherwise, insofar as such
losses, claims, damages or

                                       6

<Page>

liabilities (or actions in respect thereof) arise out of or are based upon
any untrue statement or alleged untrue statement of any material fact
contained in the registration statement under which such Registrable
Securities were registered under the 1933 Act pursuant to Article II, any
preliminary prospectus or final prospectus contained therein, or any
amendment or supplement thereof, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading,
and will reimburse the Company and each such officer, director, underwriter
and controlling person for any legal or other expenses reasonably incurred by
them in connection with investigating or defending any such loss, claim,
damage, liability or action; provided that each holder of Registrable
Securities will be liable hereunder in any such case if and only to the
extent that any such loss, claim, damage or liability arises out of or is
based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in reliance upon and in conformity with information
pertaining to such Stockholder, as such, furnished in writing to the Company
by such Stockholder specifically for use in such registration statement or
prospectus.

      (c)   Promptly after receipt by an indemnified party hereunder of
notice of the commencement of any action, such indemnified party shall, if a
claim in respect thereof is to be made against the indemnifying party
hereunder, notify the indemnifying party in writing thereof, but the omission
so to notify the indemnifying party shall not relieve the indemnifying party
from any liability which the indemnifying party may have to such indemnified
party other than under this Section 2.9 and shall only relieve the
indemnifying party from any liability which the indemnifying party may have
to such indemnified party under this Section 2.9 if and to the extent the
indemnifying party is prejudiced by such omission. In case any such action
shall be brought against any indemnified party and the indemnified party
shall notify the indemnifying party of the commencement thereof, the
indemnifying party shall be entitled to participate in and, to the extent the
indemnifying party shall wish, to assume and undertake the defense thereof
with counsel satisfactory to such indemnified party, and, after notice from
the indemnifying party to such indemnified party of the indemnifying party's
election so to assume and undertake the defense thereof, the indemnifying
party shall not be liable to such indemnified party under this Section 2.9
for any legal expenses subsequently incurred by such indemnified party in
connection with the defense thereof other than reasonable costs of
investigation and of liaison with counsel so selected; provided that, if the
defendants in any such action include both the indemnified party and the
indemnifying party and the indemnified party shall have reasonably concluded
that if the interests of the indemnified party reasonably may be deemed to
conflict with the interests of the indemnifying party, then the indemnified
party shall have the right to select a separate counsel and to assume such
legal defenses and otherwise to participate in the defense of such action,
with the expenses and fees of such separate counsel and other expenses
related to such participation to be reimbursed by the indemnifying party as
incurred.

      (d)   In order to provide for just and equitable contribution to joint
liability under the 1933 Act in any case in which either: (i) any holder of
Registrable Securities exercising rights under this Agreement, or any
controlling person of any such holder, makes a claim for indemnification
pursuant to this Section 2.9 but it is judicially determined (by the entry of
a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that
such indemnification may not be enforced in such case

                                       7

<Page>

notwithstanding the fact that this Section 2.9 provides for indemnification
in such case, or (ii) contribution under the 1933 Act may be required on the
part of any such holder or any such controlling person in circumstances for
which indemnification is provided under this Section 2.9; then, and in each
such case, the Company and such holder will contribute to the aggregate
losses, claims, damages or liabilities to which they may be subject (after
contribution from others) as is appropriate to reflect the relative fault of
the Company and such holder in connection with the statements or omissions
which resulted in such losses, claims, damages or liabilities, as well as the
relative benefit received by the Company and such holder as a result of the
offering in question; provided, that in any such case (A) no such holder will
be required to contribute any amount in excess of the public offering price
of all such Registrable Securities offered by such holder pursuant to such
registration statement, and (B) no person or entity guilty of fraudulent
misrepresentation (within the meaning Section 11 (f) of the 1933 Act) will be
entitled to contribution from any person or entity who was not guilty of such
fraudulent misrepresentation.

      2.10  CHANGES IN COMMON STOCK. If, and as often as, there is any change
in the Common Stock by way of a stock split, stock dividend, combination or
reclassification, or through a merger, consolidation, reorganization or
recapitalization, or by any other means, then appropriate adjustment shall be
made in the provisions hereof so that the rights and privileges granted
hereby shall continue with respect to the Common Stock as so changed.

      2.11  PREPARATION OF REGISTRATION STATEMENT. Whenever the Company is
registering any Common Stock under the 1933 Act and a holder of Registrable
Securities is selling any Registrable Securities under such registration or
determines that it may be a controlling person under such 1933 Act, the
Company will allow such holder and its counsel to participate in the
preparation of the registration statement, will include in the registration
statement such information as such holder may reasonably request and will
take all such other action as such holder may reasonably request.

      2.12  TRANSFERABILITY OF REGISTRATION RIGHTS. The registration rights
described herein are freely transferable by the holders of Registrable
Securities to any person to whom such holder transfers Registrable Securities.

                                  ARTICLE III

                              PRE-EMPTIVE RIGHTS

      3.1   PROCEDURES FOR EXERCISE OF PRE-EMPTIVE RIGHT TO PURCHASE
ADDITIONAL SECURITIES. If at any time prior to the closing of an initial
public offering by the Company, the Company intends to sell in excess of
$500,000 of its equity securities (in the same or a series of related
offerings) or securities convertible into equity securities, which $500,000
threshold shall be determined by taking into account the maximum amount that
is to be paid or payable for the issuance, and upon the exercise, conversion
or exchange of any such equity securities or securities convertible into
equity securities ("APPLICABLE OFFERINGS"), except for Excluded Offerings (as
hereinafter defined), the Company will, at least fifteen (15) days prior to
the sale of any securities pursuant to an Applicable Offering, notify the
Stockholders who own Preferred Stock (for purposes of this Section 3.1, each
a "HOLDER") of the Applicable Offering, including

                                       8

<Page>

the terms thereof and the number of securities offered thereby. Within
fifteen (15) days after delivery of such notice by the Company, each Holder
shall have the right to transmit a binding commitment (a "BINDING
COMMITMENT") to purchase (on the exact same terms as offered pursuant to the
Applicable Offering) and, in the event that the Company proceeds with the
Applicable Offering, it will be obligated to sell to each such Holder, that
number of securities to be sold in the Applicable Offering proportionally
equal to each such Holder's equity interest in the Company (determined on an
as-if-converted to Common Stock basis, assuming the exercise of all warrants
and other rights to acquire capital stock of the Company, but excluding any
outstanding options issued under any stock or option plan approved by the
Company's Board of Directors). Failure by a Holder to transmit a Binding
Commitment pursuant to this Section 3.1, shall be deemed a waiver in full of
such Holder's rights to purchase any of the securities to be sold in
connection with such Applicable Offering.

      3.2   EXCLUDED OFFERINGS. Notwithstanding the provisions of Section
3.1, the following issuances by the Company shall be "EXCLUDED OFFERINGS" and
shall not be considered Applicable Offerings:  (i) securities issued in any
public offering, (ii) securities issued in connection with any acquisition by
the Company of any other business or commercial enterprise where the Company
is the surviving entity, (iii) securities issued for compensatory purposes to
directors, consultants or employees of the Company or its affiliates, (iv)
securities issued upon exercise of stock options or warrants or upon the
conversion of convertible securities outstanding on the date hereof or issued
in compliance with this Article III (including shares of Common Stock
issuable upon conversion of the Preferred Stock), (v) securities issued to
financial institutions and leasing companies in connection with borrowing and
lease financing arrangements, or to landlords or service providers, (vi)
securities issued pursuant to (a) the provisions of Section 3 of the Series
04 Preferred Stock Purchase Agreement by and between the Company and the
investors who are signatories thereto, dated April 2, 2004, as may be amended
from time to time, (b) the provisions of Section 3 of the Series 04 Preferred
Stock Exchange Agreement by and between the Company and the investors who are
signatories thereto, dated April 2, 2004, as may be amended from time to
time, (c) the provisions of Section 3 of the 2005 Series 04 Preferred Stock
Purchase Agreement by and between the Company and the investors who are
signatories thereto, dated March 2, 2005, as may be amended from time to
time, (d) the provisions of Section 3 of the Purchase Agreement, and (e) such
comparable exchange rights as may granted by the Company in the future, (vii)
securities issued in connection with any joint venture, strategic alliance,
distribution or development agreement or other similar relationship or issued
for non monetary consideration, (viii) securities issued pursuant to Section
3.9 of Article FOURTH of the Company's Amended and Restated Certificate of
Incorporation, as may be amended from time to time or (ix) securities issued
upon the exercise or conversion of securities issued pursuant to (i)-(viii)
or upon the exercise or conversion of those securities.

                                  ARTICLE IV

                               VOTING AGREEMENT

      4.1   VOTING AGREEMENT. At any and all meetings (including any written
action in lieu of a meeting) of stockholders of the Company at which
directors are to be elected, each

                                       9

<Page>

Stockholder shall vote all of the voting securities of the Company now or
hereafter owned or controlled by such Stockholder to elect, as a director of
the Company, one representative (the "VERTICAL REPRESENTATIVE") designated by
the general partner of Vertical Fund I, L.P. and Vertical Fund II, L.P.,
presently The Vertical Group, L.P. (the "VERTICAL GP").

      4.2   DESIGNATION OF DIRECTOR. The initial Vertical Representative
shall be Jack Lasersohn.

      4.3   SUCCESSOR DIRECTORS. If the Vertical Representative shall cease
to serve as a director of the Company for any reason, the Vertical GP shall
have the right to designate a successor representative and each Stockholder
shall promptly vote all of his voting securities of the Company and otherwise
use his best efforts to ensure that such successor representative is duly
elected as a director.

      4.4   NOMINATION BY COMPANY. The Company shall use its best efforts to
nominate for election to the Board of Directors the Vertical Representative
designated hereunder.

                                   ARTICLE V

                                  IPO LOCK-UP

      Each Stockholder agrees that in connection with an underwritten initial
public offering of Common Stock, upon the request of the Company or the
principal underwriter managing such public offering, the Stock may not be
sold, offered for sale or otherwise disposed of without the prior written
consent of the Company or such underwriter, as the case may be, for at least
214 days after the effectiveness of the Registration Statement filed in
connection with such offering, or such longer period of time as the Board of
Directors may determine, provided that all of the Company's directors and
officers agree to be similarly bound.

                                  ARTICLE VI

                                 MISCELLANEOUS

      6.1   TERM OF AGREEMENT.

      This Agreement shall terminate with respect to (i) Section 1.3 when the
Company becomes subject to the periodic reporting requirements of Section 13
or Section 15(d) of the Exchange Act, (ii) Article II when there are no
longer any Registrable Securities, (iii) Article III upon completion of the
Company's initial public offering and (iv) Article (IV) upon completion of
the Company's initial public offering or at such time as Vertical and its
affiliates no longer hold an aggregate of 7% of the Company's Common Stock,
on a fully diluted (assuming that all warrants, options and other rights to
acquire capital stock of the Company had been exercised), as converted basis.
Notwithstanding the foregoing, this Agreement shall terminate in full upon
the sale of the Company, whether by merger, sale, or transfer of more than
fifty percent (50%) of its outstanding capital stock, or sale of
substantially all of its assets.

                                      10

<Page>

      6.2   ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
among the parties with respect to the subject matter hereof, and supersedes
all prior agreements and understandings among the parties with respect
thereto. This agreement is intended to amend and restate the Fourth Amended
Stockholders' Agreement in its entirety and upon execution hereof, the Fourth
Amended Stockholders' Agreement shall be deemed to be terminated in all
respects.

      6.3   SUCCESSORS AND ASSIGNS. This Agreement and the rights and
obligations of the parties hereunder shall inure to the benefit of, and be
binding upon their respective successors, assigns and legal representatives.

      6.4   MODIFICATION, WAIVER OR AMENDMENT. Except for the addition of
Additional Stockholders as provided in Section 6.5 hereby, neither this
Agreement nor any provision hereof can be modified, waived, amended, changed,
discharged or terminated except by an instrument in writing, signed by the
Company and each of Edward M. Giles, State Farm Mutual Automobile Insurance
Company, Vertical Fund I, L.P. and Vertical Fund II, L.P.; provided that the
agreement of any such Stockholder shall not be required if such Stockholder
(together with its affiliates) no longer holds at least fifty percent (50%)
of the Registrable Securities of the Company held by such Stockholder
(together with its affiliates) as of the date hereof. If at any time Edward
M. Giles, State Farm Mutual Automobile Insurance Company, Vertical Fund I,
L.P. and Vertical Fund II, L.P (together with their respective affiliates)
shall each no longer hold at least fifty percent (50%) of the Registrable
Securities held by each such Stockholder (together with their respective
affiliates) as of the date hereof, this Agreement and any provision hereof
may only be waived, modified, amended or terminated by a written agreement
signed by the Company and the Stockholders owning at least a majority of the
Registrable Securities then subject to this Agreement, based upon voting
power and calculated on an "as if converted" basis.

      6.5   ADDITIONAL PARTIES. Notwithstanding anything to the contrary
herein, additional persons who are officers or employees of the Company or
persons or entities who acquire shares of Common Stock of the Company or
securities of the Company convertible into Common Stock, may become parties
to this Agreement and become "Stockholders" hereunder by executing an
Additional Party Signature Page with the Company.

      6.6   GOVERNING LAW. This Agreement shall be governed by and construed
under the laws of the Commonwealth of Massachusetts without regard to the
conflicts of law provisions thereof.

      6.7   NOTICES. Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified by hand
or professional courier service or facsimile (with written confirmation) to
the address or facsimile number for such party noted on the signature page
hereof, or at such other address as such party may designate by ten (10)
days' advance written notice to the other parties.

      6.8   ADDITIONAL LEGEND. Each certificate evidencing voting securities
of the Company held by a Stockholder shall bear a legend substantially as
follows:

                                      11

<Page>

         "The shares represented by this certificate are subject to the terms
         and conditions of a certain Fifth Amended and Restated Stockholders'
         Agreement dated as of January 19, 2006, as may be amended and/or
         restated from time to time, a copy of which the Company will furnish
         to the holder of this certificate upon request and without charge."

      6.9   SEVERABILITY. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, such provision shall be
excluded from this Agreement and the balance of the Agreement shall be
interpreted as if such provision were so excluded and the remaining
provisions of the Agreement shall be enforceable in accordance with their
terms.

      6.10  REMEDIES. In case any one or more of the covenants and/or
agreements set forth in this Agreement shall have been breached by any party
hereto, the party or parties entitled to the benefit of such covenants or
agreements may proceed to protect and enforce their rights either by suit in
equity and/or by action at law, including, but not limited to, an action for
damages as a result of any such breach and/or an action for specific
performance of any such covenant or agreement contained in this Agreement.
The rights, powers and remedies of the parties under this Agreement are
cumulative and not exclusive of any other right, power or remedy which such
parties may have under any other agreement or law. No single or partial
assertion or exercise of any right, power or remedy of a party hereunder
shall preclude any other or further assertion or exercise thereof.

      6.11  CAPTIONS. The table of contents, headings and captions used in
this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

      6.12  PRONOUNS. All terms and words used in this Agreement shall be
deemed and construed to include any other number, singular or plural, and any
other gender, masculine, feminine or neuter, as the context or sense of this
Agreement or any paragraph or clause herein may require, the same as if such
words have been fully and properly written in the required number and gender.

      6.13  COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

      6.14  DISPUTE RESOLUTION. Any controversy or claim arising out of or
relating to this contract, or the breach thereof, shall be settled by
arbitration in Boston, Massachusetts administered by the American Arbitration
Association in accordance with its Commercial Arbitration Rules, and judgment
on the award rendered by the arbitrator(s) may be entered in any court having
jurisdiction thereof.

                 [Remainder of page intentionally left blank]

                                      12

<Page>

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

                                  METABOLIX INC.

                                  By: /s/ James Barber
                                     --------------------------------
                                  Name: James Barber
                                  Title: Chief Executive Officer
                                  and President

                                  STOCKHOLDERS

                                  /s/ Edward M. Giles
                                  -----------------------------------
                                  Edward M. Giles

                                  STATE FARM MUTUAL AUTOMOBILE
                                  INSURANCE CO.

                                  By:/s/ John Concklin
                                     --------------------------------
                                  Name:  John Concklin
                                  Title:  Vice President-Common
                                  Stock

                                  VERTICAL FUND II, L.P.

                                  By:The Vertical Group, L.P.
                                     Its General Partner

                                  By:/s/ Stephen D. Baksa
                                     --------------------------------
                                  Name: Stephen D. Baksa
                                  Title: General Partner

                                  VERTICAL FUND I, L.P.

                                  By: The Vertical Group, L.P.
                                     Its General Partner

                                  By:/s/ Stephen D. Baksa
                                     --------------------------------
                                  Name:  Stephen D. Baksa
                                  Title:  General Partner

<Page>

                                                                      EXHIBIT A

                                 STOCKHOLDERS

Winifred E. Alcorn
AHI/MBX Associates, LLC
Thomas G. Auchincloss, Jr.
Banc of America Securities, LLC Custodian For Benefit of Philip Meyer IRA
Rollover
James J. Barber
Rex J. Bates
Allan M. Benton
Henry E. Blair
Christopher M. Bodnar
Richard Booth
Brookstone Biotech Ventures, L.P.
Ray O. Brownlie
Brownlie Family Partnership
Joel & Joyce Buchman, as Joint Tenants with Rights of Survivorship
Andrew H. Chapman
Chestnut Capital, LLC
F. Hudnall Christopher, Jr.
Jeffrey Cianci
Roger L. Clifton
Cynthia A. Cannell Revocable Trust Dated 8/15/96
Corporate Finance Group, Inc.
Dongah Flour Mills Co., Ltd.
John Duffey
Fernanda Eberstadt
Frederick Eberstadt
Nicholas Nash Eberstadt
Joni Evans
Fiduciary Trust Company as Custodian FBO Edward M. Giles IRA #3
Steven R. Frank
Alexander J. Giacco
Edward M. Giles
Grant Gray
Elizabeth M. Greetham
John D. Hogan
Won Huh
Isles Capital, L.P.
James C. Cannell Revocable Trust Dated 8/15/96
John D. Hogan IRA
Maniv Investments, LLC
William D. and Carol F. McDonald
George McNally

<Page>

Davis U. Merwin
James M. Meyer
Philip K. Meyer
Mintz Levin Investments LLC
Michael T. Cannell Revocable Trust Dated 8/15/96
Peter F. Cannell Revocable Trust Article Third
Edward M. Muller
William L. Musser, Jr.
David and Sharon Neenan
Patrick R. D. Paul
Oliver P. Peoples
F.W. Rapp
Joseph P. Riccardo
Ridfell Investment S.A.
Rosetta N. Reusch and William H. Reusch JTWROS
Melvin J. Sallen
SIA Partnership XX
Anthony J. Sinskey
State Farm Mutual Automobile Insurance Co.
Gregory Stephanopoulos
Charles Stone
The 2000 Charles F. Stone III Living Trust DTD October 23, 2000
Pike Sullivan
The Devivo Revocable Trust dated 11-1-88
The Gwyneth Muller Irrevocable Trust - 2000, dated March 27, 2000, William
Gillen, Trustee
The Lara Muller Irrevocable Trust - 2000, dated March 27, 2000, William
Gillen, Trustee
The Paul Foundation
Vertical Fund I, L.P.
Vertical Fund II, L.P.
Charles Waggner
James B. Wallace
Wallace Family Partnership
Charles-Henri Weil
Joseph and Deborah Werner, as Joint Tenants with rights of Survivorship
James Wilbur
William B. Cannell Revocable Trust Dated 8/15/96
Williams Children's Trust dated May 22, 1996, Douglas R. Ederle, Trustee
Simon F. Williams
George F. Wood
Zillion Worldwide Inc.

                                      15

<Page>

                                                                      EXHIBIT B

                                METABOLIX, INC.

              Fifth Amended and Restated Stockholders' Agreement

                     ADDITIONAL STOCKHOLDER SIGNATURE PAGE

      By executing this signature page in the space provided, the undersigned
"Stockholder" hereby agrees to become party to and to be bound by all of the
terms and conditions of the Fifth Amended and Restated Stockholders'
Agreement by and among Metabolix, Inc. and the parties named therein and
authorizes this signature page to be attached as a counterpart to such
agreement. This Additional Stockholder Signature Page shall take effect and
shall become an integral part of the Fifth Amended and Restated Stockholders'
Agreement immediately upon acceptance hereof by the Company

      EXECUTED this         day of                            ,     .

                         --------------------------------------------
                         (print name)

                         By:
                              ---------------------------------------

                         Title:
                               --------------------------------------

                         Address:

                         --------------------------------------------
                         --------------------------------------------

                         --------------------------------------------

                         Fax:
                              ---------------------------------------

Accepted:

METABOLIX, INC.

By:
--------------------------
Name:
Title:<Page>

                                                                   EXHIBIT 10.19

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

                             LICENSE AGREEMENT

     This Agreement is made and entered into this 1st day of October, 1999, (the
"Effective Date") by and between METABOLIX, Inc. a corporation duly organized
and existing under the laws of the State of Delaware and having its principal
office at 303 Third Street, Cambridge, Massachusetts 02142 (hereinafter referred
to as "METABOLIX"), and TEPHA, Inc., a corporation duly organized under the laws
of the State of Delaware and having its principal office at 303 Third Street,
Cambridge, Massachusetts 02142 (hereinafter referred to as "TEPHA").

                                   WITNESSETH

     WHEREAS, METABOLIX, is the owner of the METABOLIX PATENT RIGHTS (as later
defined herein), and related technology, and has the right to grant licenses
under said METABOLIX PATENT RIGHTS;

     WHEREAS, METABOLIX is the licensee from the Massachusetts Institute of
Technology (hereinafter referred to as "MIT") of the MIT PATENT RIGHTS (as later
defined herein), and has the right to grant sublicenses under said MIT PATENT
RIGHTS;

     WHEREAS, METABOLIX desires to have the PATENT RIGHTS commercialized in the
FIELD OF USE, and is willing to grant a license thereunder; and

     WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

   NOW THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

* CONFIDENTIAL TREATMENT REQUESTED

<Page>

1.   DEFINITIONS

   For the purposes of this Agreement, the following words and phrases shall
have the following meanings:

     1.1.      "TEPHA" and "METABOLIX" shall include "AFFILIATES" defined as a
               related company of TEPHA or METABOLIX, respectively, the voting
               stock of which is directly or indirectly at least fifty percent
               (50%) owned and controlled by TEPHA or METABOLIX, respectively,
               an organization which directly or indirectly controls more than
               fifty percent (50%) of the voting stock of TEPHA or METABOLIX,
               respectively, and an organization the majority ownership of which
               is directly or indirectly common to the ownership of TEPHA or
               METABOLIX, respectively.

     1.2.      "PATENT RIGHTS" shall mean all of the following METABOLIX and MIT
               intellectual property, respectively, the "METABOLIX PATENT
               RIGHTS" and the MIT PATENT RIGHTS":

               1.2.1.    the United States patents listed in Appendix A;

               1.2.2.    the United States patent applications listed in
                         Appendix A and United States patent applications filed
                         after the EFFECTIVE DATE on IMPROVEMENTS, and
                         divisionals, continuations and claims of
                         continuation-in-part applications which shall be
                         directed to subject matter specifically described in
                         such patent applications, and the resulting patents;

               1.2.3.    any patents resulting from reissues or reexaminations
                         of the United States patents described in 1.2.1 and
                         1.2.2 above;

               1.2.4.    the Foreign patents listed in Appendix A;

               1.2.5.    the Foreign patent applications listed in Appendix A,
                         and divisionals, continuations and claims of
                         continuation-in-part applications which shall be
                         directed to subject matter specifically described in
                         such Foreign patent applications, and the resulting
                         patents;

* CONFIDENTIAL TREATMENT REQUESTED

                                        2
<Page>

               1.2.6.    Foreign patent applications filed after the EFFECTIVE
                         DATE on any patent application in 1.2.2 and
                         divisionals, continuations and claims of
                         continuation-in-part applications which shall be
                         directed to subject matter specifically described in
                         such patent applications, and the resulting patents;
                         and

               1.2.7.    any Foreign patents, resulting from equivalent Foreign
                         procedures to United States reissues and
                         reexaminations, of the Foreign patents described in
                         1.2.4, 1.2.5 and 1.2.6 above.

     1.3.      A "LICENSED PRODUCT" shall mean any product or part thereof
               which:

               1.3.1.    is covered in whole or in part by an issued, unexpired
                         valid claim or a pending claim contained in the PATENT
                         RIGHTS in the country in which any such product or part
                         thereof is made, used or sold; or

               1.3.2.    is manufactured by using a process or is employed to
                         practice a process which is covered in whole or in part
                         by an issued, unexpired valid claim or a pending claim
                         contained in the PATENT RIGHTS in the country in which
                         a LICENSED PROCESS is used or in which such product or
                         part thereof is used or sold.

     1.4.      A "LICENSED PROCESS" shall mean any process which:

               1.4.1.    is covered in whole or in part by an issued, unexpired
                         valid claim or a pending claim contained in the PATENT
                         RIGHTS in the country in which such process is used or
                         in which the LICENSED PRODUCT made thereby is used or
                         sold.

     1.5.      "NET SALES" shall mean TEPHA's and its sublicensees' billings for
               LICENSED PRODUCTS and LICENSED PROCESSES produced hereunder less
               the sum of the following:

               1.5.1.    discounts allowed in amounts customary in the trade;

               1.5.2.    sales, tariff duties and/or use taxes directly imposed
                         and with reference to particular sales;

               1.5.3.    outbound transportation prepaid or allowed; and

               1.5.4.    amounts allowed or credited on returns.

* CONFIDENTIAL TREATMENT REQUESTED

                                        3
<Page>

     No deduction shall be made for commissions paid to individuals whether they
     be with independent sales agencies or regularly employed by TEPHA and on
     its payroll, or for cost of collections. LICENSED PRODUCTS shall be
     considered "sold" when invoiced. "NET SALES" shall not include LICENSED
     PRODUCTS sold for clinical testing, research or development purposes. If a
     LICENSED PRODUCT or LICENSED PROCESS shall be distributed or invoiced for a
     discounted price substantially lower than customary in the trade or
     distributed at no cost to AFFILIATES of TEPHA or otherwise, NET SALES shall
     be based on the customary amount billed for such LICENSED PRODUCTS or
     LICENSED PROCESSES.

     Where the LICENSED PRODUCT is a combination product consisting of polymer
     whose composition or manufacture is covered by the PATENT RIGHTS plus other
     materials (such as a growth factor, but not, for example, filler materials)
     that are not covered by the PATENT RIGHTS, then "NET SALES" shall mean the
     NET SALES of the full product multiplied by the fully loaded manufacturing
     cost of the polymer divided by the total fully loaded manufacturing cost of
     the total combination material. When the LICENSED PRODUCT consists of a
     combination product consisting of a component made from the polymer, plus
     other components, then "NET SALES" shall mean NET SALES of the total
     product multiplied by the fully loaded manufacturing cost of the polymer
     component divided by the fully loaded manufacturing cost of the total
     product. By "fully loaded" is meant the cost of goods sold plus overhead
     allocated to production and sale thereof.

     1.6.      "FIELD OF USE" shall mean IN VIVO human and veterinary medical
               use of polymers falling within the PATENT RIGHTS, including,
               without limitation, tissue engineering, implantables, medical
               devices, drug delivery and contrast agents, but excluding medical
               disposables, surgical drapes and trays, nutritional and all other
               diagnostic uses. and excluding transgenic plant crop production
               of polymers. "IMPROVEMENT" shall mean an invention conceived
               and/or reduced to practice during the two-year period after the
               EFFECTIVE DATE and dominated by the claims of the PATENT RIGHTS
               listed on Appendix A and owned or CONTROLLED by METABOLIX or
               TEPHA (excluding any preexisting IMPROVEMENT owned or CONTROLLED
               by any entity as of the

* CONFIDENTIAL TREATMENT REQUESTED

                                        4
<Page>

               date it becomes a successor or permitted assignee of METABOLIX
               or TEPHA under Article 11).

     1.7.      "KNOW-HOW" shall mean technical, manufacturing, regulatory and
               other information, methods, specifications, samples, processes,
               procedures, formulations, test data, protocols, and trade secrets
               owned or CONTROLLED by METABOLIX or TEPHA during the two-year
               period after the EFFECTIVE DATE and relating to the PATENT RIGHTS
               or to the development, manufacture or use of any LICENSED
               PRODUCTS or LICENSED PROCESSES (excluding any preexisting
               KNOW-HOW owned or CONTROLLED by any entity as of the date it
               becomes a successor or permitted assignee of METABOLIX or TEPHA
               under Article 11).

     1.8.      "CONTROL" shall mean with respect to any IMPROVEMENTS or
               KNOW-HOW, the possession of the ability to grant a license or
               sublicense with respect thereto as provided for herein.

     1.9.      "FDA" shall mean the United States Food and Drug Administration
               or any successor agency thereof.

2.   GRANT

     2.1.      Subject to the terms and conditions of this Agreement, METABOLIX
               hereby grants to TEPHA the worldwide right and license in the
               FIELD OF USE to make, have made, use, lease, sell, offer for sale
               and import the LICENSED PRODUCTS and to practice the LICENSED
               PROCESSES until the expiration of the last to expire of the
               PATENT RIGHTS, unless this Agreement shall be sooner terminated
               according to the terms hereof.

     2.2       Under the terms of its license with MIT, METABOLIX has agreed
               that any sublicenses granted by it shall provide that the
               obligations to MIT of articles 2, 5, 7, 8, 9, 10, 12, 13 and 15
               of its license with MIT shall be binding upon the sublicensee as
               if it were a party to that license agreement. METABOLIX further
               has agreed to attach copies of these articles to sublicense
               agreements, and a copy thereof is attached hereto as Appendix C.
               To the extent of any conflict between

* CONFIDENTIAL TREATMENT REQUESTED

                                        5
<Page>

               the terms of this Agreement and Appendix C, as to the MIT PATENT
               RIGHTS only, the terms of Appendix C shall prevail.

     2.3       In order to establish a period of exclusivity for TEPHA,
               METABOLIX hereby agrees that it shall not grant any other license
               to make, have made, use, lease, sell, offer for sale or import
               LICENSED PRODUCTS or to utilize LICENSED PROCESSES in the FIELD
               OF USE and shall not practice under the PATENT RIGHTS for its own
               purposes in the FIELD OF USE during the term of this Agreement;
               provided, however, MIT has reserved the right to practice under
               the MIT PATENT RIGHTS for its own noncommercial research
               purposes.

     2.4       Within six (6) months after the EFFECTIVE DATE, METABOLIX shall
               disclose to TEPHA in writing all METABOLIX-CONTROLLED KNOW-HOW
               not previously disclosed. During the two-year period after the
               EFFECTIVE DATE, each party shall also promptly disclose to the
               other in writing on an ongoing basis all additional KNOW-HOW and
               IMPROVEMENTS. Subject to Article 13 (Confidentiality), METABOLIX
               grants TEPHA the exclusive right and license to use METABOLIX
               KNOW-HOW and METABOLIX IMPROVEMENTS in connection with its
               license hereunder to the PATENT RIGHTS in the FIELD OF USE until
               termination or expiration of this Agreement; provided, however,
               after expiration of this Agreement, TEPHA shall retain a
               perpetual, royalty-free, non-exclusive license to the METABOLIX
               KNOW-HOW. Subject to Article 13 (Confidentiality) and mutually
               agreed upon royalty and other terms, TEPHA grants METABOLIX the
               exclusive right and license to use TEPHA KNOW-HOW and TEPHA
               IMPROVEMENTS in connection with the PATENT RIGHTS outside the
               FIELD OF USE until the last to expire of any patent rights
               covering the TEPHA IMPROVEMENTS; provided, however, after
               expiration of this Agreement, METABOLIX shall retain a perpetual,
               royalty-free, non-exclusive license to the METABOLIX KNOW-HOW.

     2.5       TEPHA shall have the right to enter into sublicensing agreements
               for the rights, privileges and licenses granted hereunder. Upon
               any termination of this

* CONFIDENTIAL TREATMENT REQUESTED

                                        6
<Page>

               Agreement, sublicensees' rights shall also terminate, subject to
               Paragraph 14.6 hereof.

     2.6       TEPHA agrees to incorporate terms and conditions substantively
               similar to Articles 1, 2, 5, 7.1, 8, 9, 10, 11, 12, 13, 14.5,
               14.6, and 16 of this Agreement into its sublicense agreements,
               that are sufficient to enable TEPHA to comply with this
               Agreement.

     2.7       TEPHA agrees to forward to METABOLIX a copy of any and all
               sublicense agreements promptly upon execution by the parties.

     2.8       TEPHA shall not receive from sublicensees anything of value in
               lieu of cash payments in consideration for any sublicense under
               this Agreement, without the express prior written permission of
               METABOLIX.

     2.9       Nothing in this Agreement shall be construed to confer any rights
               upon TEPHA by implication, estoppel or otherwise as to any
               technology or patent rights of METABOLIX, MIT or any other entity
               other than the PATENT RIGHTS, regardless of whether such patent
               rights shall be dominant or subordinate to any PATENT RIGHTS.

3.   DUE DILIGENCE

     3.1.      TEPHA shall use diligent efforts to bring one or more LICENSED
               PRODUCTS or LICENSED PROCESSES to market through a thorough,
               vigorous and diligent program for exploitation of the PATENT
               RIGHTS and shall continue active, diligent development and
               marketing efforts for one or more LICENSED PRODUCTS or LICENSED
               PROCESSES throughout the term of this Agreement.

     3.2.      In addition:

               3.2.1.    TEPHA shall raise in connection with the PATENT RIGHTS
                         and allocated for expenditure for efforts under
                         Paragraphs 3.1 and 3.2, a cumulative total of
                         investment capital and/or research and development
                         funds of: * from the Effective Date. Such cumulative
                         investment capital and/or research and development
                         funds shall include funds invested or

* CONFIDENTIAL TREATMENT REQUESTED

                                       7
<Page>

                         expended by a joint venture in which TEPHA owns at
                         least a thirty-three percent (33%) interest provided
                         that such funds are used substantially for the
                         development and marketing of LICENSED PRODUCTS and
                         LICENSED PROCESSES.

               3.2.2.    TEPHA shall use commercially reasonable efforts to
                         promptly and diligently generate data and perform tests
                         and studies sufficient to file, and shall file, an
                         application for approval by the FDA of a first LICENSED
                         PRODUCT *.

               3.2.3.    TEPHA shall obtain FDA approval of such first LICENSED
                         PRODUCT *.

               3.2.4.    TEPHA shall keep METABOLIX informed of progress in its
                         efforts to develop and commercialize LICENSED PRODUCTS
                         and PROCESSES. METABOLIX shall have the right to
                         contact a representative of TEPHA periodically by
                         telephone to discuss TEPHA's progress with the
                         development of LICENSED PRODUCTS and PROCESSES and
                         sales of such LICENSED PRODUCTS and PROCESSES once
                         launched. In addition, on or before March 1 of each
                         year after the EFFECTIVE DATE until the first
                         commercial sale of a LICENSED PRODUCT, TEPHA shall make
                         a written annual summary report to METABOLIX covering
                         the preceding year ending December 31, regarding the
                         progress toward commercial use of LICENSED PRODUCTS and
                         PROCESSES. All information disclosed by TEPHA to
                         METABOLOX under this provision shall be deemed the
                         Confidential Information (as further discussed in
                         Paragraph 13.1) of TEPHA.

     3.3.      TEPHA's failure to perform in accordance with Paragraphs 3.1 and
               3.2 above shall be grounds for METABOLIX to terminate this
               Agreement pursuant to Paragraph 14.3 hereof; provided, however,
               as to Paragraphs 3.2.2 and 3.2.3, if during the cure period
               provided in Paragraph 14.3, TEPHA shall demonstrate to the
               reasonable satisfaction of METABOLIX that TEPHA shall have
               expended good faith and diligent efforts using reasonable
               resources to meet the milestone(s)

* CONFIDENTIAL TREATMENT REQUESTED

                                       8
<Page>

               and that circumstances beyond TEPHA'S control precluded TEPHA
               from performing in accordance with Paragraph 3.2.2 or 3.2.3, then
               the time for performance of such milestone(s) shall be extended
               for an additional period of six (6) months, or such other period
               as may be mutually agreed.

4.   ROYALTIES

     4.1.      For the rights, privileges and license granted hereunder, TEPHA
               shall pay royalties to METABOLIX in the manner hereinafter
               provided until the expiration of the last to expire of the PATENT
               RIGHTS or until this Agreement shall earlier be terminated:

               4.1.1.    A License Issue Fee of * which said License Issue Fee
                         shall be deemed earned and due in three parts: * in
                         investment capital and/or research and development
                         funds in connection with the PATENT RIGHTS; * due upon
                         the raising by TEPHA of * (cumulatively) in investment
                         capital and/or research and development funds in
                         connection with the PATENT RIGHTS; and * due upon the
                         raising by TEPHA of * (cumulatively) in investment
                         capital and/or research and development funds in
                         connection with the PATENT RIGHTS; provided, however,
                         the full amount of the License Issue Fee shall be due
                         on the third anniversary of the Effective Date,
                         whether or not TEPHA shall have raised such investment
                         capital and/or research and development funds.

               4.1.2.    Milestone payments as follows: * due on filing for
                         approval of the first LICENSED PRODUCT; and * due on
                         FDA approval of the first LICENSED PRODUCT.

               4.1.3.    License Maintenance Fees of * per year payable on
                         January 1, 2003 and on each subsequent January 1 during
                         the term of this Agreement; provided, however, License
                         *.

               4.1.4.    Running Royalties of * of NET SALES of LICENSED
                         PRODUCTS and LICENSED PROCESSES by TEPHA and its
                         sublicensees.

* CONFIDENTIAL TREATMENT REQUESTED

                                        9
<Page>

               4.1.5.    A * share of gross sublicensing revenue (including
                         sublicense issue fees, milestone payments, license
                         maintenance fees and similar consideration but
                         excluding sublicensing revenue from NET SALES covered
                         in Paragraph 4.1.4 above) received by LICENSEE.

     4.2.      All payments due hereunder shall be paid in full, without
               deduction of taxes or other fees which may be imposed by any
               government, except as otherwise provided in Paragraph 1.5.2.

     4.3.      No multiple royalties shall be payable because any LICENSED
               PRODUCT, its manufacture, use, lease or sale are or shall be
               covered by more than one PATENT RIGHTS patent application or
               PATENT RIGHTS patent licensed under this Agreement.

     4.4.      Royalty payments shall be paid in the United States dollars in
               Cambridge, Massachusetts, or at such other place as METABOLIX may
               reasonably designate consistent with the laws and regulations
               controlling in any foreign country. If any current conversion
               shall be required in connection with the payment of royalties
               hereunder, such conversion shall be made by using the exchange
               rate prevailing at the Chase Manhattan Bank (N.A.) on the last
               business day of the calendar quarterly reporting period to which
               such royalty payments relate.

     4.5.      To the extent that TEPHA shall obtain subsequent to the EFFECTIVE
               DATE licenses to third party patents or other intellectual
               property that are necessary to manufacture or sell LICENSED
               PRODUCTS or LICENSED PROCESSES in the FIELD OF USE, TEPHA may
               deduct from the Running Royalty due to METABOLIX under Paragraph
               4.1.4, * of the Running Royalties due on such third party patents
               or intellectual property up to an amount equal to * of the
               Running Royalties due hereunder.

5.   REPORTS AND RECORDS

     5.1.      TEPHA shall keep full, true and accurate books of account
               containing all particulars that may be necessary for the purpose
               of showing the amounts payable

* CONFIDENTIAL TREATMENT REQUESTED
                                       10
<Page>

               to METABOLIX hereunder. Said books of account shall be kept at
               TEPHA's principal place of business or the principal place of
               business of the appropriate division of TEPHA to which this
               Agreement relates. Said books and the supporting data shall be
               open at all reasonable times for * following the end of the
               calendar year to which they pertain, to the inspection of
               METABOLIX or its agents for the purpose of verifying TEPHA's
               royalty statement or compliance in other respect with this
               Agreement. Should such inspection lead to the discovery of a
               greater than * discrepancy in reporting to METABOLIX' detriment,
               TEPHA agrees to pay the full cost of such inspection.

     5.2.      TEPHA shall deliver to METABOLIX true and accurate reports,
               giving such particulars of the business conducted by TEPHA and
               its sublicensees under this Agreement as shall be pertinent to
               diligence under Article 3 and royalty accounting hereunder:
               before the first commercial sale of a LICENSED PRODUCT or
               LICENSED PROCESS, annually, on January 31 of each year; and after
               the first commercial sale of a LICENSED PRODUCT or LICENSED
               PROCESS, quarterly, within sixty (60) days after March 31, June
               30, September 30 and December 31, of each year. These reports
               shall include at least the following:

               5.2.1.    number and total billings of LICENSED PRODUCTS falling
                         solely within the METABOLIX PATENT RIGHTS manufactured,
                         used or sold by TEPHA and its sublicensees;

               5.2.2.    number and total billings for LICENSED PRODUCTS falling
                         solely within the MIT PATENT RIGHTS manufactured, used
                         or sold by TEPHA and its sublicensees;

               5.2.3.    number and total billings for LICENSED PRODUCTS falling
                         within both the METABOLIX PATENT RIGHTS and the MIT
                         PATENT RIGHTS manufactured, used or sold by TEPHA and
                         its sublicensees;

               5.2.4.    accounting for all LICENSED PROCESSES used or sold by
                         TEPHA and its sublicensees, along with a verification
                         as to each LICENSED PROCESS stating whether it shall
                         fall solely within the METABOLIX

* CONFIDENTIAL TREATMENT REQUESTED

                                       11
<Page>

                         PATENT RIGHTS, solely within the MIT PATENT RIGHTS or
                         both within the METABOLIX PATENT RIGHTS and the MIT
                         PATENTS RIGHTS.;

               5.2.5.    deductions applicable as provided in Paragraph 1.5;

               5.2.6.    Running Royalties due under Paragraph 4.1.4.;

               5.2.7.    royalties due on payments from sublicensees under
                         paragraph 4.1.5.;

               5.2.8.    total royalties due; and

               5.2.9.    names and addresses of all sublicensees of TEPHA. TEPHA
                         shall endeavor to obtain similar information from its
                         sublicensees and shall provide such information which
                         is obtained to METABOLIX.

     5.3.      With each such report submitted, TEPHA shall pay to METABOLIX the
               royalties due and payable under this Agreement. If no royalties
               shall be due, TEPHA shall so report.

     5.4.      On or before the ninetieth (90th) day following the close of
               TEPHA's fiscal year, TEPHA shall provide METABOLIX with TEPHA's
               certified financial statements for the preceding fiscal year
               including, at a minimum, a balance sheet and an operating
               statement.

     5.5.      The amounts due under Articles 4 and 6 shall, if overdue, bear
               interest until payment a per annum rate * in effect at the Chase
               Manhattan Bank (N.A.) on the due date. The payment of such
               interest shall not foreclose METABOLIX from exercising any other
               rights it may have as a consequence of the lateness of any
               payment.

6.   PATENT PROSECUTION

     6.1.      Throughout the term of this Agreement, TEPHA, at its own expense,
               shall file, prosecute and maintain those METABOLIX PATENT RIGHTS
               listed on Appendix B in METABOLIX' name; provided, however,
               METABOLIX shall be entitled to review and comment upon in a
               timely manner all actions undertaken in the prosecution of all
               patents and applications. TEPHA agrees to seek strong,

* CONFIDENTIAL TREATMENT REQUESTED

                                       12
<Page>

               broad claims in the best interest of METABOLIX and shall not
               abandon the subject matter of any substantive claim without the
               prior written permission of METABOLIX, such permission not to be
               unreasonably withheld. If TEPHA shall elect not to file,
               prosecute, or maintain any such METABOLIX PATENT RIGHT, TEPHA
               shall so notify METABOLIX in writing with at least thirty (30)
               days notice prior to any filing, action, payment or the like
               being due, in which event METABOLIX shall have the right to file,
               prosecute, or maintain such METABOLIX PATENT RIGHT, and TEPHA
               shall have no further license rights as to such METABOLIX PATENT
               RIGHT application or patent under this Agreement.

     6.2.      Payment of all out-of-pocket fees and costs relating to the
               filing, prosecution, and maintenance of those METABOLIX PATENT
               RIGHTS listed on Appendix B shall be the responsibility of TEPHA,
               whether such fees and costs were incurred before or after the
               Effective Date of this Agreement. Payment for out-of-pocket costs
               incurred by METABOLIX prior to the Effective Date shall be made
               in three parts:

               6.2.1.    Twenty-Five Percent (25%) on or before a date six (6)
                         months from the Effective Date of this Agreement;

               6.2.2.    Twenty-Five Percent (25%) on or before a date nine (9)
                         months from the Effective Date of this Agreement;

               6.2.3.    The remaining Fifty Percent (50%) on or before a date
                         fifteen (15) months from the Effective Date of this
                         Agreement.

7.   INFRINGEMENT

     7.1.      Each party shall inform the other promptly in writing of any
               alleged infringement of the PATENT RIGHTS by a third party and of
               any available evidence thereof.

     7.2.      During the term of this Agreement, TEPHA shall have the right,
               but shall not be obligated, to prosecute at its own expense all
               infringements of the PATENT RIGHTS in the FIELD OF USE and, in
               furtherance of such right, METABOLIX

* CONFIDENTIAL TREATMENT REQUESTED

                                       13
<Page>

               hereby agrees that TEPHA may join METABOLIX as a party plaintiff
               in any such suit, without expense to METABOLIX. The total cost of
               any such infringement action commenced solely by TEPHA shall be
               borne by TEPHA. In the event that TEPHA shall have exercised its
               right to bring an action, TEPHA shall be responsible for
               defending against any counterclaims alleging invalidity or
               unenforceability of a PATENT RIGHT and for prosecuting the action
               through to settlement or other final disposition. *.

     7.3.      If within six (6) months after having been notified of any
               alleged infringement, TEPHA shall have been unsuccessful in
               persuading the alleged infringer to desist and shall not have
               brought and shall not be diligently prosecuting an infringement
               action, or if TEPHA shall notify METABOLIX at any time prior
               thereto of its intention not to bring suit against any alleged
               infringer, then, and in those events, only, METABOLIX shall have
               the right, but shall not be obligated, to prosecute at its own
               expense any infringement of the PATENTS RIGHTS in the FIELD of
               USE. In furtherance of such right, TEPHA hereby agrees that
               METABOLIX may include TEPHA as a party plaintiff in any such
               suit, without expense to TEPHA. The total cost of any such
               infringement action commenced or defended solely by METABOLIX
               shall be borne by METABOLIX, and METABOLIX shall be responsible
               for defending against any counterclaims alleging invalidity or
               unenforceability of a PATENT RIGHT.

     7.4.      Any recovery of damages by the prosecuting party for any such
               suit shall be applied first in satisfaction of any unreimbursed
               expenses and legal fees of such party relating to the suit, and
               next toward reimbursement of METABOLIX for any royalties past due
               or withheld and applied pursuant to Paragraph 7.2, if applicable.
               *.

     7.5.      In the event of the institution of any suit by a third party
               against METABOLIX, TEPHA or its sublicensees for patent
               infringment involving the PATENT RIGHTS in the FIELD OF USE, the
               party sued shall promptly notify the other party in writing.
               TEPHA shall have the right, but not the obligation, to defend
               such suit at its own expense. If TEPHA shall elect not to defend,
               TEPHA shall

* CONFIDENTIAL TREATMENT REQUESTED

                                       14
<Page>

               promptly notify METABOLIX. METABOLIX shall have the right, but
               not the obligation, to defend such suit at its expense.

     7.6.      If TEPHA shall exercise its rights pursuant to Section 7.5 to
               defend the PATENT RIGHTS, *:

               7.6.1.    If the enforceability of all material claims in such
                         PATENT RIGHT claiming the LICENSED PRODUCT or PROCESS
                         is upheld by a court or other legal or administrative
                         tribunal from which no appeal is or can be taken, *
                         or

               7.6.2.    If one or more claims in such PATENT RIGHT covering the
                         LICENSED PRODUCT or PROCESS shall be held to be invalid
                         or otherwise unenforceable by a court or other legal or
                         administrative tribunal in any country from which no
                         appeal is or can be taken or the scope thereof is
                         modified and, as a result such PATENT RIGHT no longer
                         offers substantial protection to a LICENSED PRODUCT or
                         PROCESS in such country, *.

     7.7.      In any suit as either party may institute to enforce or defend
               the PATENT RIGHTS pursuant to this Agreement, the other party
               hereto shall, at the request and expense of the party initiating
               such suit, cooperate in all respects and, to the extent possible,
               have its employees testify when requested and make available
               relevant records, papers, information, samples, specimens and the
               like. The parties shall keep one another informed of the status
               of and of their respective activities regarding any litigation or
               settlement thereof concerning the PATENT RIGHTS in the FIELD of
               USE or LICENSED PRODUCTS or PROCESSES ; provided, however, that
               no settlement or consent judgement or other voluntary final
               disposition of any suit defended or action brought by a party
               pursuant to this Article 7 may be entered into without the
               consent of the other party, such consent not to be unreasonably
               withheld or delayed. As to the MIT PATENT RIGHTS, no settlement,
               consent judgement or other voluntary final disposition of the
               suit may be entered into without the consent of MIT which consent
               shall not unreasonably be withheld. TEPHA shall indemnify MIT
               against any order for

* CONFIDENTIAL TREATMENT REQUESTED

                                       15
<Page>

               costs that may be made against MIT in proceedings commenced and
               defended solely by TEPHA.

     7.8.      TEPHA, during the period of this Agreement, shall have the sole
               right in accordance with the terms and conditions herein to
               sublicense any alleged infringer for future use of the PATENT
               RIGHTS in the FIELD OF USE.

8.   PRODUCT LIABILITY

     8.1.      TEPHA shall at all times during the term of this Agreement and
               thereafter, indemnify, defend and hold METABOLIX and MIT, their
               directors, trustees, officers, employees and affiliates, harmless
               against all claims and expenses, arising out of *.

     8.2.      Prior to the first use of a LICENSED PRODUCT for humans, TEPHA
               shall obtain and carry in full force and effect commercial,
               general liability insurance, including product liability
               insurance, which shall protect TEPHA, METABOLIX, and MIT with
               respect to events covered by Paragraph 8.1 above. Such insurance
               shall be written by a reputable insurance company authorized to
               do business in the Commonwealth of Massachusetts, shall list
               METABOLIX and MIT as additional named insureds thereunder, shall
               be endorsed to include product liability coverage and shall
               require thirty (30) days written notice to be given to METABOLIX
               and MIT prior to any cancellation or material change thereof. The
               limits of such insurance shall not be less than * per occurrence
               with an aggregate of * for personal injury including death;
               and * per occurrence with an aggregate of * for property
               damage. TEPHA shall provide METABOLIX with Certificates of
               Insurance evidencing the same.

     8.3.      EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
               NEITHER PARTY, NOR MIT, NOR THEIR RESPECTIVE DIRECTORS, TRUSTEES,
               OFFICERS, EMPLOYEES, AND AFFILIATES MAKE ANY REPRESENTATIONS OR
               EXTEND ANY WARRANTIES OF

* CONFIDENTIAL TREATMENT REQUESTED

                                       16
<Page>

               ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO
               WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
               VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE
               ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.
               NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION
               MADE OR WARRANTY GIVEN BY EITHER PARTY OR BY MIT THAT THE
               PRACTICE OF THE LICENSES GRANTED HEREUNDER SHALL NOT INFRINGE THE
               PATENT RIGHTS OR OTHER INTELLECTUAL OR PROPRIETARY RIGHTS OF ANY
               THIRD PARTY. * TEPHA, MIT OR THEIR RESPECTIVE DIRECTORS,
               TRUSTEES, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR
               INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING
               ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS,
               REGARDLESS OF WHETHER SUCH PARTY SHALL OR M.I.T. BE ADVISED,
               SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
               POSSIBILITY OF THE FOREGOING.

9.   EXPORT CONTROLS

     9.1.      TEPHA acknowledges that it is subject to United States laws and
               regulations controlling the export of technical data, computer
               software, laboratory prototypes and other commodities (including
               the Arms Export Control Act, as amended and the United States
               Department of Commerce Export Administration Regulations). The
               transfer of such items may require a license from the cognizant
               agency of the United States Government and/or written assurances
               by TEPHA that TEPHA shall not export data or commodities to
               certain foreign countries without prior

* CONFIDENTIAL TREATMENT REQUESTED

                                       17
<Page>

               approval of such agency. METABOLIX neither represents that a
               license shall not be required nor that, if required, it shall be
               issued.

10.  NON-USE OF NAMES

     10.1.     Except as required by law or in raising funding, neither party
               shall use the names or trademarks of the other, nor of MIT, nor
               any adaptation thereof, nor the names of any of the other party's
               or MIT's employees, in any advertising, promotional or sales
               literature without prior written consent obtained from such
               party, or MIT, or said employee, in each case, such consent not
               to be unreasonably withheld, except that TEPHA may state that it
               is licensed by METABOLIX, or MIT, as applicable, under one or
               more of the patents and/or applications comprising the METABOLIX
               PATENT RIGHTS, or the MIT PATENT RIGHTS, respectively. TEPHA may,
               however, use the name of any employee of METABOLIX who is a
               consultant or member of an advisory board of TEPHA, with their
               permission, and provided, also, that their affiliation with
               METABOLIX is identified.

11.  ASSIGNMENT

     11.1.     Except as expressly provided in Article 2, neither party shall
               directly or indirectly sell, transfer, assign, or delegate in
               whole or in part this Agreement, or any rights, duties,
               obligations or liabilities under this Agreement (collectively
               "assign"), by operation of law or otherwise without the prior
               written consent of the other party, such consent not to be
               unreasonably withheld or delayed; provided, however, so long as
               the assignee shall not be a competitor of the other party, either
               party shall have the right to assign all of its rights, duties,
               obligations and liabilities under this Agreement to any AFFILIATE
               or in connection with any sale, merger, consolidation,
               recapitalization or reorganization involving in each case the
               sale of all or substantially all of the capital stock of the
               party or the assets of such party to which this Agreement
               relates. This Agreement shall inure to the benefit of and be

* CONFIDENTIAL TREATMENT REQUESTED

                                       18
<Page>

               binding upon the permitted successors and assigns of METABOLIX
               and TEPHA.

12.  DISPUTE RESOLUTION

     12.1.     Except for the right of either party to apply to a court of
               competent jurisdiction for a temporary restraining order, a
               preliminary injunction or other equitable relief to preserve the
               status quo or to prevent irreparable harm, and except for any
               dispute relating to patent validity or infringement, any and all
               claims, disputes or controversies arising under, out of or in
               connection with the Agreement, shall be mediated in good faith.
               The party raising such dispute shall promptly advise the other
               party of such claim, dispute or controversy in a writing which
               describes in reasonable detail the nature of such dispute. If the
               parties by their senior management representatives shall be
               unable to resolve the dispute within thirty ( 30 ) days, then by
               no later than forty ( 40 ) business days after the recipient has
               received such notice of dispute, each party shall have selected
               for itself a representative who shall have the authority to bind
               such party, and shall additionally have advised the other party
               in writing of the name and title of such representative. By no
               later than sixty (60 ) business days after the date of such
               notice of dispute, such representatives shall schedule a date for
               a mediation hearing with the Cambridge Dispute Settlement Center
               or Endispute Inc. in Cambridge, Massachusetts. The parties shall
               enter into good faith mediation and shall share the costs
               equally. If the representatives of the parties have not been able
               to resolve the dispute within thirty (30) business days after
               such mediation hearing, the parties shall have the right to
               pursue any other remedies legally available to resolve such
               dispute in either the Courts of the Commonwealth of
               Massachusetts, or in the United States District Court for the
               District of Massachusetts, to whose jurisdiction for such
               purposes METABOLIX and TEPHA each hereby irrevocably consents and
               submits.

* CONFIDENTIAL TREATMENT REQUESTED

                                       19
<Page>

     12.2.     Notwithstanding the foregoing, nothing in this Article shall be
               construed to waive any rights or timely performance of any
               oblations under this Agreement.

13.  CONFIDENTIALTIY

     13.1.     Both METABOLIX and TEPHA agree that all information disclosed to
               the other party shall be deemed "Confidential Information" of the
               disclosing party. In particular, "Confidential Information" shall
               be deemed to include, but not be limited to, KNOW-HOW, trade
               secrets, information, ideas, inventions, materials, samples,
               processes, procedures, methods, formulations, protocols,
               packaging designs and materials, test data, future development
               plans, "Product" launch date, technological know-how and
               engineering, manufacturing, regulatory, marketing, servicing,
               sales, or financial matters relating to the disclosing party and
               its business.

     13.2.     During the term of this Agreement and thereafter each party shall
               maintain all Confidential Information in confidence and shall not
               disclose any Confidential Information to any third party or use
               any such information for any unauthorized purpose. Each party may
               use such Confidential Information only to the extent required to
               accomplish the purposes of this Agreement. Both parties shall
               take precautions as each normally takes with its own confidential
               and proprietary information to prevent disclosure to third
               parties, but no less than reasonable precautions.

     13.3.     Both parties agree that, notwithstanding the above, the
               obligations of confidentiality and nonuse shall not apply to:

               13.3.1.   Information that at the time of disclosure is, or
                         thereafter becomes, generally known or available to the
                         public, through no wrongful act or failure to act on
                         the part of the receiving party;

               13.3.2.   Information that was known by or in the possession of
                         the receiving party at the time of receiving such
                         information from the disclosing party, as evidenced by
                         written records;

* CONFIDENTIAL TREATMENT REQUESTED

                                       20
<Page>

               13.3.3.   Information obtained by the receiving party from a
                         third-party source who is not breaching a commitment of
                         confidentiality to the disclosing party by revealing
                         such information to the receiving party;

               13.3.4.   Information that is developed independently by the
                         receiving party without use of confidential information
                         of the other party, as evidenced by written records;

               13.3.5.   Information that is the subject of a granted written
                         permission to disclose that is issued by the disclosing
                         party to the other party;

               13.3.6.   Information that is required to be disclosed pursuant
                         to the law, by request of the FDA or other government
                         authority or for medical or safety reasons, but only to
                         the extent required to be disclosed by the FDA or other
                         government authority; or

               13.3.7.   Information provided to consultants, subcontractors or
                         agents for purposes consistent with this Agreement
                         pursuant to a non-disclosure agreement with said
                         parties.

     13.4.     Both Parties shall make diligent efforts to ensure that all
               employees, consultants, agents and subcontractors who may have
               access to Confidential Information of the other party, and any
               other third parties who might have access to Confidential
               Information, shall sign nondisclosure agreements consistent with
               the terms set forth in this Section. No Confidential Information
               shall be disclosed to any employees, subcontractors, agents,
               consultants or third parties who do not have a need to receive
               such information for the purposes of this Agreement.

14.  TERMINATION

     14.1.     If TEPHA shall cease to carry on its business, this Agreement
               shall terminate upon notice by METABOLIX, except as provided in
               Article 11 (Assignment).

     14.2.     Should TEPHA fail to make any payment whatsoever due and payable
               to METABOLIX hereunder, METABOLIX shall have the right to
               terminate this Agreement effective on sixty (60) days' notice,
               unless TEPHA shall make all such

* CONFIDENTIAL TREATMENT REQUESTED

                                       21
<Page>

               payments to METABOLIX, within said sixty (60) day period. Upon
               the expiration of the sixty (60) day period, if TEPHA shall not
               have made all such payments to METABOLIX, the rights, privileges
               and license granted hereunder shall automatically terminate.

     14.3.     Upon any material breach or default of this Agreement by TEPHA,
               other than those occurrences set out in Paragraphs 14.1 and 14.2
               hereinabove, which shall always take precedence in that order
               over any material breach or default referred to in this Paragraph
               14.3, METABOLIX shall have the right to terminate this Agreement
               and the rights, privileges and license granted hereunder
               effective on one hundred and twenty (120) days' notice to TEPHA.
               Such termination shall become automatically effective unless
               TEPHA shall have cured any such material breach or default prior
               to the expiration of the one hundred and twenty (120) day period.
               Upon any material breach or default of this Agreement by
               METABOLIX, TEPHA shall have the right to terminate this Agreement
               and the rights, privileges and license granted hereunder
               effective on one hundred and twenty (120) days' notice to
               METABOLIX. Such termination shall become automatically effective
               unless METABOLIX shall have cured any such material breach or
               default prior to the expiration of the one hundred and twenty
               (120) day period.

     14.4.     TEPHA shall have the right to terminate this Agreement at any
               time on six (6) months' notice to METABOLIX, and upon payment of
               all amounts due METABOLIX through the effective date of the
               termination.

     14.5.     Upon termination of this Agreement for any reason, nothing herein
               shall be construed to release either party from any obligation
               that matured prior to the effective date of such termination; and
               Articles 1, 8, 9, 10, 12, 13, 14.5, 14.6, and 16 shall survive
               any such termination. TEPHA and any sublicensee thereof may,
               however, after the effective date of such termination, sell all
               LICENSED PRODUCTS in inventory, and complete LICENSED PRODUCTS in
               the process of manufacture at the time of such termination and
               sell the same, provided that TEPHA shall pay to METABOLIX the
               Running Royalties thereon as required by

* CONFIDENTIAL TREATMENT REQUESTED

                                       22
<Page>

               Article 4 of this Agreement and shall submit the reports required
               by Article 5 hereof on the sales of LICENSED PRODUCTS.

     14.6.     Upon termination of this Agreement for any reason, any sublicense
               not then in default shall continue in full force and effect
               except that METABOLIX shall be substituted in place of the TEPHA,
               and METABOLIX shall have no obligations under such sublicense
               beyond their obligations herein.

     14.7.     Upon termination of this AGREEMENT for any reason *, to all
               information then in TEPHA's possession relevant to the
               commercialization of LICENSED PRODUCTS and/or LICENSED PROCESSES,
               including, but not limited to, KNOW-HOW and IMPROVEMENTS owned or
               controlled by TEPHA as of the effective date of termination
               (whether such know-how and improvements shall be owned or
               CONTROLLED by TEPHA during the two-year period after the
               EFFECTIVE DATE or at any time during the term of this Agreement),
               research results, toxicology data, assays, preclinical data,
               prototypes, manufacturing processes including cell lines and
               unused, unexpired amounts of LICENSED PRODUCTS, clinical results,
               regulatory submissions, suppliers and customer lists. *.

15.  PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

     15.1.     Any payment, notice or other communication pursuant to this
               Agreement shall be sufficiently made or given on the date of
               mailing if sent to such party by certified first class mail,
               postage prepaid, return receipt requested addressed to it at its
               address below or as it shall designate by written notice given to
               the other party:

     In the case of METABOLIX:
     President
     METABOLIX, Inc.
     303 Third Street
     Cambridge, Massachusetts 02142

     In the case of TEPHA:
     President

* CONFIDENTIAL TREATMENT REQUESTED

                                       23
<Page>

     TEPHA, Inc.
     303 Third Street
     Cambridge, Massachusetts 02142

16.  MISCELLANEOUS PROVISIONS

     16.1.     This Agreement shall be construed, governed, interpreted and
               applied in accordance with the laws of the Commonwealth of
               Massachusetts, U.S.A., except that questions affecting the
               construction and effect of any patent shall be determined by the
               law of the country in which the patent was granted.

     16.2.     The parties hereto acknowledge that this Agreement sets forth the
               entire Agreement and understanding of the parties hereto as to
               the subject matter hereof, and shall not be subject to any change
               or modification except by the execution of a written instrument
               subscribed to by the parties hereto.

     16.3.     The provisions of this Agreement are severable, and in the event
               that any provisions of this Agreement shall be determined to be
               invalid or unenforceable under any controlling body of the law,
               such invalidity or unenforceability shall not in any way affect
               the validity or enforceability of the remaining provisions
               hereof.

     16.4.     The failure of either party to assert a right hereunder or to
               insist upon compliance with any term or condition of this
               Agreement shall not constitute a waiver of that right or excuse a
               similar subsequent failure to perform any such term or condition
               by the other party.

     16.5.     TEPHA agrees to mark the LICENSED PRODUCTS sold in the United
               States with all applicable United States patent numbers. All
               LICENSED PRODUCTS shipped to or sold in other countries shall be
               marked in such a manner as to conform with the patent laws and
               practice of the country of manufacture or sale.

   IN WITNESS WHEREOF, the parties have duly executed this Agreement the day
and year set forth below.

* CONFIDENTIAL TREATMENT REQUESTED

                                       24
<Page>

METABOLIX, INC.

By:    /s/ Edward M. Muller
       ---------------------------
Name:  Edward M. Muller
       ---------------------------
Title: President
       ---------------------------
Date:  10/1/99
       ---------------------------

TEPHA, INC.

By:    /s/ Simon F. Williams
       ---------------------------
Name:  Simon F. Williams
       ---------------------------
Title: President
       ---------------------------
Date:  October 1, 1999
       ---------------------------

* CONFIDENTIAL TREATMENT REQUESTED

                                       25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]